Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of C4 Therapeutics patents

List of C4 Therapeutics patents

List of Chelsea Therapeutics International patents

List of Curtis Industries, Llc. patents

List of TriCipher patents

List of awards received by Divock Origi

List of companies in Strawberry Creek Ventures's investment portfolio

Patents where

Current Assignee

Name

is

C4 Therapeutics

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11459335 N/O-linked Degrons and Degronimers for protein degradation	Patent 11459335 was granted and assigned to C4 Therapeutics on October, 2022 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11459335	October 4, 2022
	‌ US Patent 11802131 Glutarimides for medical treatment	Patent 11802131 was granted and assigned to C4 Therapeutics on October, 2023 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11802131	October 31, 2023
	‌ US Patent 11787802 Dihydrobenzimidazolones for medical treatment	Patent 11787802 was granted and assigned to C4 Therapeutics on October, 2023 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11787802	October 17, 2023
	‌ US Patent 10905768 Heterocyclic degronimers for target protein degradation	Patent 10905768 was granted and assigned to C4 Therapeutics on February, 2021 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	10905768	February 2, 2021
	‌ US Patent 11584748 Spirocyclic compounds	Patent 11584748 was granted and assigned to C4 Therapeutics on February, 2023 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11584748	February 21, 2023
	‌ US Patent 11185592 Spirocyclic degronimers for target protein degradation	Patent 11185592 was granted and assigned to C4 Therapeutics on November, 2021 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11185592	November 30, 2021
	‌ US Patent 11623929 Spirocyclic compounds	Patent 11623929 was granted and assigned to C4 Therapeutics on April, 2023 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11623929	April 11, 2023
	‌ US Patent 11401256 Dihydroquinolinones for medical treatment	Patent 11401256 was granted and assigned to C4 Therapeutics on August, 2022 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11401256	August 2, 2022
	‌ US Patent 11254672 Dihydrobenzimidazolones for medical treatment	Patent 11254672 was granted and assigned to C4 Therapeutics on February, 2022 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11254672	February 22, 2022
	‌ US Patent 11673902 Isoindolinone and indazole compounds for the degradation of EGFR	Patent 11673902 was granted and assigned to C4 Therapeutics on June, 2023 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11673902	June 13, 2023
	‌ US Patent 11524949 Degraders and Degrons for targeted protein degradation	Patent 11524949 was granted and assigned to C4 Therapeutics on December, 2022 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11524949	December 13, 2022
	‌ US Patent 10646575 Heterocyclic degronimers for target protein degradation	Patent 10646575 was granted and assigned to C4 Therapeutics on May, 2020 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	10646575	May 12, 2020
	‌ US Patent 10849982 C3-carbon linked glutarimide degronimers for target protein degradation	Patent 10849982 was granted and assigned to C4 Therapeutics on December, 2020 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	10849982	December 1, 2020
	‌ US Patent 10660968 Spirocyclic degronimers for target protein degradation	Patent 10660968 was granted and assigned to C4 Therapeutics on May, 2020 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	10660968	May 26, 2020
	‌ US Patent 11691972 Compounds for targeted degradation of BRD9	Patent 11691972 was granted and assigned to C4 Therapeutics on July, 2023 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11691972	July 4, 2023
	‌ US Patent 11407732 Tricyclic degraders of Ikaros and Aiolos	Patent 11407732 was granted and assigned to C4 Therapeutics on August, 2022 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11407732	August 9, 2022
	‌ US Patent 11753397 Cereblon binders for the degradation of ikaros	Patent 11753397 was granted and assigned to C4 Therapeutics on September, 2023 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11753397	September 12, 2023
	‌ US Patent 11992531 C	Patent 11992531 was granted and assigned to C4 Therapeutics on May, 2024 by the United States Patent and Trademark Office.	C4 Therapeutics	C4 Therapeutics		United States Patent and Trademark Office	11992531	May 28, 2024

18 results

0 selected

18 results

0 selected